Wei Bao, MD
Internal Medicine · City Of Industry, CANPI 1437199304
Payments from drug & device makers
Across 903 payments — averaging $80.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$58K
- AstraZeneca$3K
- Amgen$2K
- Novo Nordisk$1K
- Kowa Pharmaceuticals America, Inc.$1K
- Esperion Therapeutics, Inc.$837
- plus $5K from 29 others
What the payments were for
- Consulting fees$5,0307%
- Speaking & faculty fees$46,40064%
- Travel & lodging$3,1624%
- Food & beverage$17,20224%
- Education$4611%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 262 | $58,171 |
| AstraZeneca | 88 | $3,071 |
| Amgen | 110 | $2,385 |
| Novo Nordisk | 121 | $1,348 |
| Kowa Pharmaceuticals America, Inc. | 48 | $1,097 |
| Esperion Therapeutics, Inc. | 31 | $837 |
| Johnson & Johnson | 48 | $583 |
| Astellas Pharma US Inc | 12 | $570 |
| Novartis | 21 | $479 |
| Amarin Pharma, Inc. | 20 | $479 |
| Lilly USA, LLC | 21 | $460 |
| Bayer | 16 | $458 |
| Idorsia Pharmaceuticals US Inc | 14 | $356 |
| Merck | 14 | $344 |
| GSK | 10 | $303 |
| Radius Health, Inc. | 14 | $272 |
| Boehringer Ingelheim | 10 | $196 |
| Lexicon Pharmaceuticals, Inc. | 5 | $124 |
| AbbVie(2 entities) | 6 | $91 |
| Vivus LLC | 4 | $85 |
| Sanofi-aventis U.S. LLC | 3 | $69 |
| Phathom Pharmaceuticals, Inc. | 3 | $65 |
| Scilex Pharmaceuticals Inc. | 3 | $63 |
| Arbor Pharmaceuticals, Inc. | 3 | $60 |
| E.r. Squibb & Sons, L.L.C. | 3 | $59 |
| Edwards Lifesciences | 2 | $38 |
| Eisai Inc. | 2 | $35 |
| Dexcom, Inc. | 2 | $35 |
| Almatica Pharma LLC | 1 | $21 |
| Ironwood Pharmaceuticals, Inc | 1 | $20 |
| Alvogen Inc | 1 | $19 |
| Pfizer | 1 | $18 |
| Avanos Medical | 1 | $16 |
| Aytu Biopharma, Inc. | 1 | $12 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$72,255 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 510 | $389,507 |
| RybelsusSemaglutide | 195 | $215,728 |
| VemlidyTenofovir Alafenamide | 132 | $182,569 |
| VascepaIcosapent Ethyl | 325 | $151,199 |
| OzempicSemaglutide | 99 | $120,139 |
| CreonLipase/Protease/Amylase | 61 | $93,536 |
| LinzessLinaclotide | 145 | $91,112 |
| JardianceEmpagliflozin | 97 | $79,920 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 33 | $77,122 |
| ProliaDenosumab | 41 | $66,293 |
| KerendiaFinerenone | 87 | $65,929 |
| MyrbetriqMirabegron | 107 | $59,841 |
| XareltoRivaroxaban | 64 | $49,573 |
| Icosapent Ethyl | 166 | $43,803 |
| JanuviaSitagliptin Phosphate | 60 | $42,615 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $3,071 | $412,671545 claims |
| Novo NordiskRybelsus, Ozempic | $1,348 | $335,867294 claims |
| AbbVieCreon, Linzess, Restasis, Namzaric | $91 | $223,955254 claims |
| GileadVemlidy | $58,171 | $182,569132 claims |
| AmgenEvenity (2 Syringes), Prolia | $2,385 | $143,41474 claims |
| Boehringer IngelheimJardiance | $196 | $79,92097 claims |
| BayerKerendia | $458 | $65,92987 claims |
| Johnson & JohnsonXarelto, Invokana | $583 | $60,75176 claims |
| Astellas Pharma US IncMyrbetriq | $570 | $59,841107 claims |
| MerckJanuvia, Steglatro | $344 | $47,86773 claims |
| PfizerEliquis | $18 | $31,31739 claims |
| Esperion Therapeutics, Inc.Nexlizet | $837 | $30,75169 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in City Of Industry
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.